Muscle Relaxant Drugs Market Size & Share, by Therapeutic Group (Neuromuscular Blockers, Spasmolytic), Formulation (Cyclobenzaprine, Carisoprodol, Chlorzoxazone), Route of Administration (Oral, Injectable), End-user (Hospital Pharmacy, Retail Pharmacy) - SWOT Analysis, Competitive Strategic Insights, Regional Trends 2025-2037

Growth Drivers

• Increasing Sedentary Lifestyle and Decreasing Activity Levels – is a crucial reason amongst all other reasons responsible for increasing muscle weakness and musculoskeletal diseases, and is expected to drive the demand for muscle relaxant drugs in the projected period. For instance, global estimates show 81% of adolescents and 1 in 4 adults do not indulge in enough physical activity. Levels of inactivity in economically developed countries are as high as 70%.
• Rising Number of Patients with Lower Back Pain - according to the World Health Organization, 570 million people are suffering from low back pain worldwide, contributing to 7.4% of years lived with disability (YLDs) across the globe.
• Upsurge in the Number of People Suffering from Osteoarthritis (OA) – it was found that there were 527.81 million prevalent cases of OA globally in 2019.
• Growing Geriatric Population - according to the World Health Organization in 2019, there are 1 billion people aged 60 years and older. The number is expected to increase to 1.4 billion by 2030 and 2.1 billion by 2050.
• Rising Number of Cases Related to Fibromyalgia – as per estimates, fibromyalgia affects approximately 4 million US adults, about 2% of the total adult population.

Challenges

• Restrictions on the Use of Muscle Relaxants – which are mostly restricted for pregnant women and alcohol-addicted people. Muscle relaxants when combined with alcohol, may result in confusion, drowsiness, and errors in judgment.
• Side effects Associated with Liver Dysfunctional Problems and Respiratory Organs
• Short-term Relief Provider